---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-005180"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:38:49.639418+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Corvus Q2 net loss $8M, cash $74.4M; soquelitinib atopic dermatitis data shows deeper EASI reduction

## Summary
- Net loss $8.0M for Q2 2025 vs $4.3M Q2 2024; R&D expenses $7.9M (up from $4.1M).
- Cash, equivalents, securities $74.4M as of June 30, 2025; warrant exercise proceeds $35.7M in Q2.
- Soquelitinib Phase 1 atopic dermatitis: cohort 3 mean EASI reduction 64.8% at day 28 vs 54.6% for cohorts 1-2 and 34.4% placebo.
- 50% of evaluable cohort 3 patients had ≥4 point itch reduction (PP-NRS) at day 28; Phase 2 on track by year-end.
- Phase 3 PTCL registrational trial enrolling; cash expected to fund operations into Q4 2026.

## SEC filing metadata
- accession: 0001171843-25-005180
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000117184325005180/0001171843-25-005180-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000117184325005180/f8k_080725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-005180
- JSON: https://secwatch.observer/filing/0001171843-25-005180.json
- Plain text: https://secwatch.observer/filing/0001171843-25-005180.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.